All News
Different B cells depletion strategies in SARDs highlighted by Georg Schett
From low and short lived depletion achieved w/ drugs to sustained deep tissular depletion with CAR T cells leading to potential immune reset
@RheumNow #APLAR25 https://t.co/t35lrzEomF
Aurelie Najm AurelieRheumo ( View Tweet)
Juvenile Lupus: some new mechanistic data
Circulating Treg population are expanded in SLE and in particular in Lupus Nephritis compared to HC
Naive Treg display specific molecular features in particular over expression of FCRL3 and TLR5 showing new pathways to explore in https://t.co/RuMtWRkpYB
Aurelie Najm AurelieRheumo ( View Tweet)
PAH, when associated with ILD in CTD, worsens prognosis, and poses challenges for treatment
Summary of when PAH should be assessed in patients with ILD and when to perform a right heart catheterization by Prof Kuwana
@RheumNow #APLAR25 https://t.co/g4x4ENzc9k
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Dr. Alberta Hoi graphically presents the difference bet acute confusional states & chronic cognitive changes in #lupus patients presenting with NP symptoms.
NPSLE continues to pose a diagnostic challenge bec pts may present with more than one syndrome complex
@RheumNow #APLAR25 https://t.co/4nYTo1fzVz
sheila RHEUMarampa ( View Tweet)
How to treat CTD ILD?
A comparative slide summarizing ACR/BSR and EULAR treatment guidelines
Emphasis on combination of Immunosuppressant and Antifibrotics
@RheumNow #APLAR25 https://t.co/gLSht6QKh5
Aurelie Najm AurelieRheumo ( View Tweet)
“Listen to the patient, he is telling you the diagnosis”. – Sir William Osler
Dr. John Cush RheumNow ( View Tweet)
A framework for treatment stratified approach in CTD-ILD, by Dr Low Hsiu Ling
Based on
-ILD extent
-Risk of progression
-Biology: fibrosis/inflammation
-Safety
-Other manifestations
@RheumNow #APLAR25 https://t.co/ma5KugzBHy
Aurelie Najm AurelieRheumo ( View Tweet)
‼️More reasons why we should avoid steroids in #lupus patients
@RheumNow #APLAR25 https://t.co/a5IeutJ5mi
Links:
sheila RHEUMarampa ( View Tweet)
Why shall we screen all patients with SSc for ILD?
Focusing screening strategy on patients « at risk » misses 25% of patients with ILD
ILD being the main cause of mortality in SSc
@RheumNow #APLAR25 https://t.co/djzCTdZoVb
Aurelie Najm AurelieRheumo ( View Tweet)
The overall prevalence of #osteoporosis in SLE is ~33-40% and is due to several factors with GC therapy being one of them.
Monitor DXA every 6-12 months (vs. 2 yrs for standard OP)
☝️Screen for GIOP
☝️Treat accordingly - once on GCs & esp w/long-term use
@RheumNow #APLAR25 https://t.co/E9FJDHrBUo
Links:
sheila RHEUMarampa ( View Tweet)
Paradigm shift in CTD PAH
-Early triple therapy in patients with intermediate and high risk
-Sotatercept,
a blocker of activin-Smad2/3 signaling
have increased survival importantly
Data presented by Dr Khanna
@RheumNow #APLAR25 https://t.co/Z4yA6DwtOb
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
An important message from Prof. @XBaraliakos on D2M-axSpA:
Re-evaluate your diagnosis & check for comorbids before labelling pts as tx-refractory or difficult-to-manage.
consider other causes: FM, other causes of pain
@RheumNow #APLAR25 @rheumarhyme @marklagacmd https://t.co/Lo0yShOK0P
Links:
sheila RHEUMarampa ( View Tweet)
Drivers of costs associated with economic costs of RMDs in Asia Pacific
-Traditional medicine
-Loss of income much higher if worker as opposed to unpaid household labor so high impact of gender roles
-Impact of out of pocket health payments due to « catastrophic spendings » in https://t.co/sptwGE7J2V
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Prof. Aletaha shares their AutoPiX project - using AI to develop quantitative biomarkers.
Something to look forward to since imaging remains an important diagnostic tool in #rheumatology
@RheumNow #APLAR25 @rheumarhyme https://t.co/WExT9amazz
Links:
sheila RHEUMarampa ( View Tweet)
Update on Rheumatology workforce shortage in Asia-Pacific
Date presented by Dr Ahmad
Number of Rheumatologists per 100000 inhabitants across @APLAR_org countries
-3 in Japan
-1.3 in Australia, Hong Kong, Singapore
-0.03 in Pakistan
As a result: delayed diagnosis for patients! https://t.co/Hycqtp8BtY
Aurelie Najm AurelieRheumo ( View Tweet)
Peter Taylor on extra articular manifestations of RA
Keep an eye on RA patients’ glomerular function
RA patients have increased risk of CKD
Systematic review >1million pts
Risk Ratio 1.52
@RheumNow #APLAR25 https://t.co/5iZwtmvwSR
Aurelie Najm AurelieRheumo ( View Tweet)
Hyperferritinemia is common in Hyperinflammatory syndromes but is a hallmark of Macrophage activation syndrome and Sepsis; and is a poor prognostic sign too. MAS is excessive activation of T-lymphocytes & macrophages leading to cytokine storm & multi-organ damage. https://t.co/MUKXC0Tw3M
Dr. John Cush RheumNow ( View Tweet)
🆕 Intro to ILD (Part I): the essentials
🫁 Definition & basics
🔬 Key pathology patterns
🧑⚕️ Clinical approach
📋 What rheums need to know
⬇️ Download & learn more: https://t.co/7RzpTDOjwa
Created by @MithuRheum | via @RheumNow for our Rheum to Breathe: ILD Campaign https://t.co/D9d97bqcD5
Dr. John Cush RheumNow ( View Tweet)
💥 New week, new quiz.
Take 90 seconds. Prove you're the rheum news MVP.
📈 Track your accuracy
🏁 Race to the top of the leaderboard
🎯 Review what you missed
Take the RheumIQ quiz ➡️ https://t.co/CASRQjoYrB https://t.co/FCjkqud0y4
Links:
Dr. John Cush RheumNow ( View Tweet)
Lessons Learned in Neuropsychiatric SLE
Dr. Sheila Reyes, The Philippines, reports highlights from a session on neuropsychiatric systemic lupus erythematosus, presented at the APLAR 2025 Congress in Fukuoka, Japan.
https://t.co/Dh1GQnBhvg https://t.co/wX5FgpIq7C
Dr. John Cush RheumNow ( View Tweet)
